Argenx’s VYVGART Transforming CIDP Treatment

Argenx Se (ARGX) has released an update.

Argenx SE’s groundbreaking ADHERE study, published in The Lancet Neurology, showcases the effectiveness of VYVGART Hytrulo in treating Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a rare neuromuscular disorder. This largest clinical trial of its kind demonstrated a 61% reduction in disease relapse risk and marked improvements in patient mobility and strength. VYVGART Hytrulo is also recognized as the only FDA-approved neonatal Fc receptor blocker, affirming its innovative impact on CIDP treatment.

For further insights into ARGX stock, check out TipRanks’ Stock Analysis page.